Incyte (INCY) Scheduled to Post Earnings on Tuesday

Incyte (NASDAQ:INCY) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.87 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Incyte had a net margin of 16.17% and a return on equity of 12.56%. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the company earned $0.44 EPS. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Stock Performance

Shares of Incyte stock opened at $51.92 on Tuesday. The company has a market capitalization of $11.66 billion, a PE ratio of 19.59, a PEG ratio of 1.21 and a beta of 0.65. Incyte has a 12 month low of $50.27 and a 12 month high of $75.74. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $57.34 and its 200 day simple moving average is $57.86.

Analyst Upgrades and Downgrades

INCY has been the topic of several research analyst reports. Truist Financial dropped their price objective on Incyte from $91.00 to $84.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. William Blair reaffirmed an “outperform” rating on shares of Incyte in a research note on Tuesday, February 6th. BMO Capital Markets raised their price objective on Incyte from $58.00 to $64.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 14th. Royal Bank of Canada reissued a “sector perform” rating and issued a $65.00 price target on shares of Incyte in a research note on Monday, March 25th. Finally, Bank of America dropped their price target on Incyte from $69.00 to $67.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 13th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $76.07.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.